|
🐜
|
Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
16 auth.
N. Nagot,
A. Ouedraogo,
V. Foulongne,
I. Konaté,
H. Weiss,
L. Vergne,
M. Defer,
D. Djagbare,
A. Sanon,
J. Andonaba,
...
P. Becquart,
M. Segondy,
R. Vallo,
A. Sawadogo,
P. Van de Perre,
P. Mayaud
|
8 |
2007 |
8
🐜
|
|
🐜
|
The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study
15 auth.
C. Laurent,
N. Diakhaté,
Ndeye Fatou Ngom Gueye,
Mame Awa Touré,
P. Salif Sow,
Mame Awa Faye,
M. Gueye,
I. Lanièce,
C. Touré Kane,
F. Liégeois,
...
L. Vergne,
S. Mboup,
Salif Badiane,
I. Ndoye,
E. Delaporte
|
8 |
2002 |
8
🐜
|
|
🦁
|
Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients
12 auth.
L. Vergne,
M. Peeters,
E. Mpoudi-Ngolé,
A. Bourgeois,
F. Liégeois,
Coumba Touré‐Kâne,
...
S. Mboup,
C. Mulanga-Kabeya,
E. Saman,
J. Jourdan,
J. Reynes,
E. Delaporte
|
7 |
2000 |
7
🦁
|
|
🐜
|
Long-Term Benefits of Highly Active Antiretroviral Therapy in Senegalese HIV-1-Infected Adults
14 auth.
C. Laurent,
N. F. Ngom Guèye,
C. Ndour,
P. M. Guèye,
Martin Diouf,
N. Diakhaté,
N. C. Toure Kane,
I. Lanièce,
Adama Ndir,
L. Vergne,
...
I. Ndoye,
S. Mboup,
P. Sow,
E. Delaporte
|
7 |
2005 |
7
🐜
|
|
🐜
|
Characterization of a Highly Replicative Intergroup M/O Human Immunodeficiency Virus Type 1 Recombinant Isolated from a Cameroonian Patient
9 auth.
M. Peeters,
F. Liégeois,
Ndongo Torimiro,
A. Bourgeois,
E. Mpoudi,
L. Vergne,
...
E. Saman,
E. Delaporte,
S. Saragosti
|
7 |
1999 |
7
🐜
|
|
🐜
|
Binding of Human Immunodeficiency Virus Type 1 gp120 to CXCR4 Induces Mitochondrial Transmembrane Depolarization and Cytochromec-Mediated Apoptosis Independently of Fas Signaling
8 auth.
Rodolphe Roggero,
V. Robert-Hebmann,
S. Harrington,
J. Roland,
L. Vergne,
S. Jaleco,
...
C. Devaux,
M. Biard-Piechaczyk
|
7 |
2001 |
7
🐜
|
|
🐜
|
Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial
12 auth.
A. Ouedraogo,
N. Nagot,
L. Vergne,
I. Konaté,
H. Weiss,
M. Defer,
...
V. Foulongne,
A. Sanon,
J. Andonaba,
M. Segondy,
P. Mayaud,
P. Van de Perre
|
6 |
2006 |
6
🐜
|
|
🦁
|
Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage.
11 auth.
L. Vergne,
A. Bourgeois,
E. Mpoudi-Ngolé,
R. Mougnutou,
J. Mbuagbaw,
F. Liégeois,
...
C. Laurent,
C. Butel,
L. Zekeng,
E. Delaporte,
M. Peeters
|
6 |
2003 |
6
🦁
|
|
🐜
|
Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG.
12 auth.
C. Montavon,
Coumba Touré‐Kâne,
F. Liégeois,
E. Mpoudi,
A. Bourgeois,
L. Vergne,
...
Perret Jl,
Annie Boumah,
E. Saman,
S. Mboup,
E. Delaporte,
M. Peeters
|
6 |
2000 |
6
🐜
|
|
🐜
|
Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution.
10 auth.
M. Peeters,
E. Esu-Williams,
L. Vergne,
C. Montavon,
C. Mulanga-Kabeya,
T. Harry,
...
A. Ibironke,
D. Lesage,
D. Patrel,
E. Delaporte
|
6 |
2000 |
6
🐜
|
